Aclaris Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
October 13 2015 - 11:48AM
Aclaris Therapeutics, Inc. (Nasdaq:ACRS) today announced the
closing of its initial public offering of 5,750,000 shares of its
common stock at a price to the public of $11.00 per share, which
includes the exercise in full by the underwriters of their option
to purchase up to 750,000 additional shares of common stock. All of
the shares in the offering were offered by Aclaris. The aggregate
net proceeds to Aclaris, after underwriting discounts and
commissions and estimated offering expenses, are expected to be
$56.5 million. The common stock began trading on The NASDAQ Global
Select Market on October 7, 2015 under the ticker symbol "ACRS."
Jefferies LLC and Citigroup Global Markets Inc. acted as joint
book-running managers for the offering. William Blair &
Company, L.L.C. acted as a co-manager.
The offering was made only by means of a prospectus. A copy of
the final prospectus relating to these securities may be obtained
from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone at (877) 547-6340 or by email at
prospectus_department@jefferies.com, or Citigroup Global Markets
Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by telephone at (800) 831-9146, or by
email at prospectus@citi.com.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
October 6, 2015.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage specialty
pharmaceutical company focused on identifying, developing, and
commercializing novel drugs to address unmet needs in dermatology.
Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania.
CONTACT: Aclaris Contact
Frank Ruffo
Chief Financial Officer
484-324-7933
investors@aclaristx.com
Investor Contact
Patricia L. Bank
Westwicke Partners
Managing Director
415-513-1284
patti.bank@westwicke.com
Media Contact
Mike Beyer
Sam Brown, Inc.
312-961-2502
mikebeyer@sambrown.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024